Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Savara Plunges On Failure Of Late-Stage Study On Molgradex

By Zacks Investment ResearchStock MarketsJun 12, 2019 09:50PM ET
www.investing.com/analysis/savara-plunges-on-failure-of-latestage-study-on-molgradex-200431269
Savara Plunges On Failure Of Late-Stage Study On Molgradex
By Zacks Investment Research   |  Jun 12, 2019 09:50PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Savara Inc. (NASDAQ:SVRA) announced that its lead pipeline candidate, Molgradex, failed to meet the primary endpoint in the pivotal phase III study — IMPALA — evaluating it in autoimmune alveolar pulmonary proteinosis (aPAP), a rare lung disorder.

Shares of the company crashed 71% following the news. However, Savara’s shares have rallied 39.6% so far this year compared with industry’s increase of 5.5%.

The IMPALA study evaluated Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with aPAP compared to placebo for improvement in alveolar-arterial oxygen gradient (A-aDO2) as its primary endpoint. The study evaluated two dose administrations — once daily continuous administration of and once daily in seven-day intermittent cycles — of 300 µg Molgradex over 24 weeks.

Data from the study demonstrated average improvement of 12.1 mmHg in patients receiving Molgradex administered once daily continuously compared to an improvement of 8.8 mmHg for placebo. However, the treatment difference of 4.6 mmHg failed to meet the primary endpoint.

Molgradex also failed to achieve improvement of statistical significance in two key secondary endpoints – the six-minute walk distance (6MWD) and requirement for whole lung lavage (“WLL”).

However, the candidate achieved an improvement of statistical significance of 7.6 points compared to placebo in one of the key secondary endpoints of the St. George’s Respiratory Questionnaire (“SGRQ”), a measure of quality of life.

Although Molgradex failed to meet the primary endpoint, results from the study demonstrates that the candidate has potential to be an important pharmacological treatment option for patients with aPAP.

Savara is planning to meet with regulatory authorities to discuss the study results and the future development path for Molgradex.

Apart from aPAP, the company is also developing Molgradex in a mid-stage study as a treatment for patients with nontuberculous mycobacterial lung infection. The company also has another late-stage candidate, AeroVanc, which is being evaluated in a phase III study for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Enrollment in the study is expected to be completed in the third quarter.

Zacks Rank & Stocks to Consider

Savara currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Fibrocell Science Inc (NASDAQ:FCSC) , Assertio Therapeutics, Inc (NASDAQ:ASRT) and Auris Medical Holding (NASDAQ:EARS) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Fibrocell Science’s loss estimates have narrowed from $1.38 to $1.31 for 2019 and from $1.32 to $1.13 for 2020 over the past 60 days. The stock has gained 29.4% year to date.

Assertio’s earnings estimates have increased from 78 cents to 88 cents for 2019 and from 91 cents to 95 cents 2020 over the past 60 days.

Auris’ loss estimates have narrowed from $11.60 to $2.58 for 2019 and from $16.80 to $3.77 for 2020 over the past 60 days.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Fibrocell Science Inc (FCSC): Free Stock Analysis Report

Auris Medical Holding AG (EARS): Free Stock Analysis Report

ASSERTIO THERAPEUTICS, INC (ASRT): Free Stock Analysis Report

Mast Therapeutics, Inc. (SVRA): Free Stock Analysis Report

Original post

Zacks Investment Research
Savara Plunges On Failure Of Late-Stage Study On Molgradex
 

Related Articles

Savara Plunges On Failure Of Late-Stage Study On Molgradex

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email